558 related articles for article (PubMed ID: 24021501)
1. A randomized placebo-controlled trial of electroencephalographic (EEG) neurofeedback in children with attention-deficit/hyperactivity disorder.
van Dongen-Boomsma M; Vollebregt MA; Slaats-Willemse D; Buitelaar JK
J Clin Psychiatry; 2013 Aug; 74(8):821-7. PubMed ID: 24021501
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive effects of neurofeedback in adolescents with ADHD: a randomized controlled trial.
Bink M; van Nieuwenhuizen C; Popma A; Bongers IL; van Boxtel GJ
J Clin Psychiatry; 2014 May; 75(5):535-42. PubMed ID: 24922488
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
4. Behavioral Effects of Neurofeedback Compared to Stimulants and Physical Activity in Attention-Deficit/Hyperactivity Disorder: A Randomized Controlled Trial.
Geladé K; Janssen TW; Bink M; van Mourik R; Maras A; Oosterlaan J
J Clin Psychiatry; 2016 Oct; 77(10):e1270-e1277. PubMed ID: 27631143
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
6. Does EEG-neurofeedback improve neurocognitive functioning in children with attention-deficit/hyperactivity disorder? A systematic review and a double-blind placebo-controlled study.
Vollebregt MA; van Dongen-Boomsma M; Buitelaar JK; Slaats-Willemse D
J Child Psychol Psychiatry; 2014 May; 55(5):460-72. PubMed ID: 24168522
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
[TBL] [Abstract][Full Text] [Related]
8. [Neurofeedback for the treatment of attention-deficit/hyperactivity disorder (ADHD) in childhood and adolescence].
Holtmann M; Stadler C; Leins U; Strehl U; Birbaumer N; Poustka F
Z Kinder Jugendpsychiatr Psychother; 2004 Jul; 32(3):187-200. PubMed ID: 15357015
[TBL] [Abstract][Full Text] [Related]
9. Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial.
Schönenberg M; Wiedemann E; Schneidt A; Scheeff J; Logemann A; Keune PM; Hautzinger M
Lancet Psychiatry; 2017 Sep; 4(9):673-684. PubMed ID: 28803030
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
11. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial Investigating the Effects of Neurofeedback, Methylphenidate, and Physical Activity on Event-Related Potentials in Children with Attention-Deficit/Hyperactivity Disorder.
Janssen TW; Bink M; Geladé K; van Mourik R; Maras A; Oosterlaan J
J Child Adolesc Psychopharmacol; 2016 May; 26(4):344-53. PubMed ID: 26771913
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
[TBL] [Abstract][Full Text] [Related]
14. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial into the effects of neurofeedback, methylphenidate, and physical activity on EEG power spectra in children with ADHD.
Janssen TW; Bink M; Geladé K; van Mourik R; Maras A; Oosterlaan J
J Child Psychol Psychiatry; 2016 May; 57(5):633-44. PubMed ID: 26748531
[TBL] [Abstract][Full Text] [Related]
16. Neurofeedback and standard pharmacological intervention in ADHD: a randomized controlled trial with six-month follow-up.
Meisel V; Servera M; Garcia-Banda G; Cardo E; Moreno I
Biol Psychol; 2013 Sep; 94(1):12-21. PubMed ID: 23665196
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
18. A proposed multisite double-blind randomized clinical trial of neurofeedback for ADHD: need, rationale, and strategy.
Kerson C;
J Atten Disord; 2013 Jul; 17(5):420-36. PubMed ID: 23590978
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
